Clinical utility of the neutrophil elastase inhibitor sivelestat for the treatment of acute respiratory distress syndrome

Therapeutics and Clinical Risk Management

Volumn 10, Issue 1, 2014, Pages 621-629

  Aikawa, Naoki ^a   Kawasaki, Yasushi ^b  

^a KEIO UNIVERSITY   (Japan)

^b ONO PHARMACEUTICAL CO   (Japan)

Author keywords

Acute lung injury; Mortality; Pharmacotherapy; Systemic inflammatory response syndrome; Ventilator free days

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CORTICOSTEROID; CREATININE; GAMMA GLUTAMYLTRANSFERASE; LACTATE DEHYDROGENASE; LEUKOCYTE ELASTASE; NEUROMUSCULAR BLOCKING AGENT; NITRIC OXIDE; NITROGEN; SIVELESTAT; UREA; UROBILINOGEN;

ACUTE LUNG INJURY; ADULT RESPIRATORY DISTRESS SYNDROME; ANEMIA; ARTIFICIAL VENTILATION; ASPIRATION PNEUMONIA; BLEEDING; CLINICAL FEATURE; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; ENZYME ACTIVITY; EOSINOPHILIA; HEPATOBILIARY DISEASE; HUMAN; HYPERKALEMIA; HYPOXEMIA; INCIDENCE; INJECTION SITE PHLEBITIS; LENGTH OF STAY; LOW DRUG DOSE; LUNG INFILTRATE; LYMPHATIC SYSTEM DISEASE; MOLECULAR PATHOLOGY; MORTALITY; NONHUMAN; OUTCOME ASSESSMENT; PATIENT POSITIONING; POLYURIA; PROTEIN FUNCTION; RASH; REVIEW; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; THORAX RADIOGRAPHY; THROMBOCYTOPENIA; THROMBOCYTOSIS;

EID: 84905705589     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: 10.2147/TCRM.S65066     Document Type: Review

References (48)

1. Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J Med. 2000;342(18):1334-1349.
2. Rubenfeld GD, Herridge MS. Epidemiology and outcomes of acute lung injury. Chest. 2007;131(2):554-562.
3. Tomashefski JF Jr. Pulmonary pathology of the acute respiratory syndrome. Clin Chest Med. 2000;21(3):435-466.
4. Kawabata K, Hagio T, Matsuoka S. The role of neutrophil elastase in acute lung injury. Eur J Pharmacol. 2002;451(1):1-10.
5. Idell S, Kucich U, Fein A, et al. Neutrophil elastase-releasing factors in bronchoalveolar lavage from patients with adult respiratory distress syndrome. Am Rev Respir Dis. 1985;132(5):1098-1105.
6. Rocker GM, Wiseman MS, Pearson D, et al. Diagnostic criteria for adult respiratory distress syndrome: time for reappraisal. Lancet. 1989;1(8630):120-123.
7. Donnelly SC, MacGregor I, Zamani A, et al. Plasma elastase levels and the development of the adult respiratory distress syndrome. Am J Respir Crit Care Med. 1995;151(5):1428-1433.
8. Tönz M, Mihaljevic T, von Segesser LK, et al. Acute lung injury during cardiopulmonary bypass. Are the neutrophils responsible? Chest. 1995;108(6):1551-1556.
9. Bernard GR, Artigas A, Brigham KL, et al. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med. 1994;149(3 Pt 1):818-824.
10. ARDS Def inition Task Force; Ranieri VM, Rubenfeld GD, Thompson BT, et al. Acute respiratory distress syndrome: the Berlin Definition. JAMA. 2012;307(23):2526-2533.
11. The Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med. 2000;342(18):1301-1308.
12. Guérin C, Reignier J, Richard JC, et al. Prone positioning in severe acute respiratory distress syndrome. N Engl J Med. 2013;368(23): 2159-2168.
13. Spieth PM, Zhang H. Pharmacological therapies for acute respiratory distress syndrome. Curr Opin Crit Care. 2014;20(1):113-121.
14. Wheeler AP, Bernard GR. Acute lung injury and the acute respiratory distress syndrome: a clinical review. Lancet. 2007;369(9572): 1553-1564.
15. Wajanaponsan N, Reade MC, Milbrandt EB. Steroids in late ARDS? Crit Care. 2007;11(4):310.
16. Aldabbagh T, Milbrandt EB, Linden PK. Steroids in early ARDS? Crit Care. 2007;11(3):308.
17. Papazian L, Forel JM, Gacouin A, et al. Neuromuscular blockers in early acute respiratory distress syndrome. N Engl J Med. 2010;363:1107-1116.
18. Japanese Respiratory Society for ARDS. Clinical practice guideline for acute lung injury and acute respiratory distress syndrome. Nihon Kokyuki Gakkai Zasshi. 2010;Suppl:1-101. Japanese.
19. Havemann K, Gramse M. Physiology and pathophysiology of neutral proteinases of human granulocytes. Adv Exp Med Biol. 1984;167:1-20.
20. Bedard M, McClure CD, Schiller NL, et al. Release of interleukin-8, interleukin-6, and colony-stimulating factors by upper airway epithelial cells: implications for cystic fibrosis. Am J Respir Cell Mol Biol. 1993;9(4):455-462.
21. Kohri K, Ueki IF, Nadel JA. Neutrophil elastase induces mucin production by ligand-dependent epidermal growth factor receptor activation. Am J Physiol Lung Cell Mol Physiol. 2002;283(3): L531-L540.
22. Travis J, Salvesen GS. Human plasma proteinase inhibitors. Annu Rev Biochem. 1983;52:655-709.
23. Weiss SJ. Tissue destruction by neutrophils. N Engl J Med. 1989;320(6):365-376.
24. Sandhaus RA, Turino G. Neutrophil elastase-mediated lung disease. COPD. 2013;10 Suppl 1:60-63.
25. Kawabata K, Hagio T, Matsuoka S. Pharmacological profile of a specific neutrophil elastase inhibitor, sivelestat sodium hydrate. Nihon Yakurigaku Zasshi. 2003;122(2):151-160. Japanese.
26. Kawabata K, Hagio T, Matsumoto S, et al. Delayed neutrophil elastase inhibition prevents subsequent progression of acute lung injury induced by endotoxin inhalation in hamsters. Am J Respir Crit Care Med. 2000;161(6):2013-2018.
27. Hagio T, Nakao S, Matsuoka H, et al. Inhibition of neutrophil elastase activity attenuates complement-mediated lung injury in the hamster. Eur J Pharmacol. 2001;426(1-2):131-138.
28. Sakamaki F, Ishizaka A, Urano T, et al. Effect of a specific neutrophil elastase inhibitor, ONO-5046, on endotoxin-induced acute lung injury. Am J Respir Crit Care Med. 1996;153(1):391-397.
29. Kubo K, Kobayashi T, Hayano T, et al. Effects of ONO-5046, a specific neutrophil elastase inhibitor, on endotoxin-induced lung injury in sheep. J Appl Physiol. 1994;77(3):1333-1340.
30. Kishima H, Takeda S, Miyoshi S, et al. Microvascular permeability of the non-heart-beating rabbit lung after warm ischemia and reperfusion: role of neutrophil elastase. Ann Thorac Surg. 1998;65(4):913-918.
31. Miyazaki Y, Inoue T, Kyi M, et al. Effects of a neutrophil elastase inhibitor (ONO-5046) on acute pulmonary injury induced by tumor necrosis factor alpha (TNF alpha) and activated neutrophils in isolated perfused rabbit lungs. Am J Respir Crit Care Med. 1998;157(1): 89-94.
32. Hagio T, Matsumoto S, Nakao S, et al. Elastase inhibition reduced death associated with acid aspiration-induced lung injury in hamsters. Eur J Pharmacol. 2004;488(1-3):173-180.
33. Hagio T, Kishikawa K, Kawabata K, et al. Inhibition of neutrophil elastase reduces lung injury and bacterial count in hamsters. Pulm Pharmacol Ther. 2008;21(6):884-891.
34. Belaaouaj A, McCarthy R, Baumann M, et al. Mice lacking neutrophil elastase reveal impaired host defense against gram negative bacterial sepsis. Nat Med. 1998;4(5):615-618.
35. Akimoto A, Mori H, Namba T, et al. The effects of sivelestat sodium hydrate (ONO-5046 Na) on neutrophil phylaxis function in vitro. Jpn Pharmacol Ther. 2003;31:85-91.
36. Zeiher BG, Matsuoka S, Kawabata K, Repine JE. Neutrophil elastase and acute lung injury: prospects for sivelestat and other neutrophil elastase inhibitors as therapeutics. Crit Care Med. 2002;30(5):S281-S287.
37. Tamakuma S, Ogawa M, Aikawa N, et al. Relationship between neutrophil elastase and acute lung injury in humans. Pulm Pharmacol Ther. 2004;17(5):271-279.
38. Zeiher BG, Artigas A, Vincent JL, et al. Neutrophil elastase inhibition in acute lung injury: results of the STRIVE study. Crit Care Med. 2004;32(8):1695-1702.
39. Aikawa N, Ishizaka A, Hirasawa H, et al. Reevaluation of the efficacy and safety of the neutrophil elastase inhibitor, sivelestat, for the treatment of acute lung injury associated with systemic inflammatory response syndrome; a phase IV study. Pulm Pharmacol Ther. 2011;24(5):549-554.
40. Iwata K, Doi A, Ohji G, et al. Effect of neutrophil elastase inhibitor (sivelestat sodium) in the treatment of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS): a systematic review and meta-analysis. Intern Med. 2010;49(22):2423-2432.
41. Suda K, Kitagawa Y, Ozawa S, et al. Neutrophil elastase inhibitor improves postoperative clinical courses after thoracic esophagectomy. Dis Esophagus. 2007;20(6):478-486.
42. Hayashida K, Fujishima S, Sasao K, et al. Early administration of sivelestat, the neutrophil elastase inhibitor, in adults for acute lung injury following gastric aspiration. Shock. 2011;36(3):223-227.
43. Tsuboko Y, Takeda S, Mii S, et al. Clinical evaluation of sivelestat for acute lung injury/acute respiratory distress syndrome following surgery for abdominal sepsis. Drug Des Devel Ther. 2012;6:273-278.
44. Hayakawa M, Katabami K, Wada T, et al. Sivelestat (selective neutrophil elastase inhibitor) improves the mortality rate of sepsis associated with both acute respiratory distress syndrome and disseminated intravascular coagulation patients. Shock. 2010;33(1):14-18.
45. Miyoshi S, Hamada H, Ito R, et al. Usefulness of a selective neutrophil elastase inhibitor, sivelestat, in acute lung injury patients with sepsis. Drug Des Devel Ther. 2013;7:305-316.
46. Elaspol® (sivelestat sodium hydrate) [package insert]. Osaka, Japan: Ono Pharmaceutical Co., Ltd; 2002. Available from http://www.info.pmda.go.jp/downfiles/ph/PDF/180188_3999422D1020_1_09.pdf. Accessed July 10, 2014. Japanese.
47. Aikawa N, Fujishima S, Kobayashi M, et al. Cost-minimisation analysis of sivelestat for acute lung injury associated with systemic inflammatory response syndrome. Pharmacoeconomics. 2005;23(2):169-181.
48. Tamakuma S, Shiba T, Hirasawa H, et al. A phase III clinical study of a neutrophil elastase inhibitor; ONO-5046•Na in SIRS patients. Rinshoiyaku. 1998;14:289-318. Japanese.